BUY Lupin Limited — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred 1–3 months)13 May 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Lupin wins US FDA nod for sodium zirconium cyclosilicate to treat hyperkalemia
NewsCnbc-Tv18·10 Aug · 2d ago
Lupin announced that its Sodium Zirconium Cyclosilicate for Oral Suspension has been approved in the United States.
BSE · Company Update·10 Aug · 2d ago
6 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days
Advisor consensus · adjacent horizon·10 Aug · 3d ago
Lupin Q1 PAT rises 16 pc at Rs 1,417 cr
NewsEt-Markets·7 Aug · 5d ago
Lupin Q1 results driven by strong US sales; stock slips from day's high
NewsCnbc-Tv18·7 Aug · 6d ago
1 advisor has an active long-term SELL call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·9 Aug · 4d ago
US tariff threat drags Nifty Pharma 1.3% lower at close; Lupin, PPL Pharma lead decline
NewsHbl·22 Jul · 3w ago
Top Gainers & Losers on 22 July: Bandhan Bank, PG Electroplast, Lupin, Delhivery, Voltas, IndiGo among top losers
NewsLivemint·22 Jul · 3w ago
US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline
NewsHbl·22 Jul · 3w ago
Gland Pharma, Lupin, Dr Reddy's: All Nifty Pharma Stocks In Red After Trump's Drug Tariff Plan
NewsNdtv-Profit·22 Jul · 3w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.